(Q36987492)

17 August 2017

1 reference

title

Pharmacodynamics: biological activity of targeted therapies in clinical trials (English)

1 reference

17 August 2017

1 reference

Rojo F

1

1 reference

17 August 2017

Dalmases A

series ordinal

2

1 reference

17 August 2017

Corominas JM

series ordinal

3

1 reference

17 August 2017

Albanell J

series ordinal

4

1 reference

17 August 2017

1 October 2007

1 reference

Clinical and Translational Oncology

17 August 2017

1 reference

17 August 2017

9

1 reference

17 August 2017

10

1 reference

17 August 2017

634-644

1 reference

https://scigraph.springernature.com/pub.10.1007/s12094-007-0116-2

17 August 2017

0 references

cites work

Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab

1 reference

12 December 2020

Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor

1 reference

12 December 2020

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

12 December 2020

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

12 December 2020

Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer

1 reference

12 December 2020

Targeting epidermal growth factor receptor in lung cancer

1 reference

12 December 2020

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

12 December 2020

The Akt-mTOR tango and its relevance to cancer

1 reference

12 December 2020

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

12 December 2020

The ubiquitin-proteasome pathway: on protein death and cell life

1 reference

12 December 2020

Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale

1 reference

12 December 2020

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

12 December 2020

The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells

1 reference

12 December 2020

Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment

1 reference

12 December 2020

mTOR-targeted therapy of cancer with rapamycin derivatives

1 reference

12 December 2020

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.

1 reference

12 December 2020

The proteasome--an emerging therapeutic target in cancer

1 reference

12 December 2020

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

12 December 2020

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

12 December 2020

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies

1 reference

12 December 2020

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells

1 reference

12 December 2020

Phase I studies of ZD1839 in patients with common solid tumors

1 reference

12 December 2020

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

1 reference

12 December 2020

Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients

1 reference

12 December 2020

Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor

1 reference

12 December 2020

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

1 reference

12 December 2020

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

1 reference

12 December 2020

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

1 reference

12 December 2020

Proteasome inhibition: a novel approach to cancer therapy

1 reference

12 December 2020

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

1 reference

12 December 2020

Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.

1 reference

12 December 2020

Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments

1 reference

12 December 2020

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

12 December 2020

Angiogenesis in cancer and other diseases

1 reference

12 December 2020

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

1 reference

12 December 2020

PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).

1 reference

12 December 2020

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

1 reference

12 December 2020

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

1 reference

12 December 2020

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

12 December 2020

Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma

1 reference

12 December 2020

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

1 reference

12 December 2020

Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity

1 reference

12 December 2020

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

1 reference

12 December 2020

Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.

1 reference

12 December 2020

Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells

1 reference

12 December 2020

Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib

1 reference

12 December 2020

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

12 December 2020

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

12 December 2020

Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer

1 reference

12 December 2020

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

12 December 2020

4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis

1 reference

12 December 2020

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

12 December 2020

Proteasome inhibition measurements: clinical application

1 reference

12 December 2020

10.1007/S12094-007-0116-2

Identifiers

DOI

1 reference

17 August 2017

1 reference